Lexeo Therapeutics, Inc. Common Stock (LXEO)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	160.27 mm	160.27 mm	160.27 mm	160.27 mm	160.27 mm	160.27 mm
Cash burn (monthly)	5.99 mm	(no burn)	10.51 mm	7.78 mm	176.00 k	1.37 mm
Cash used (since last report)	30.43 mm	n/a	53.43 mm	39.54 mm	894.45 k	6.96 mm
Cash remaining	129.85 mm	n/a	106.84 mm	120.73 mm	159.38 mm	153.31 mm
Runway (months of cash)	21.7	n/a	10.2	15.5	905.6	111.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

LXEO institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	95	73	+30.1%
Opened positions	30	17	+76.5%
Closed positions	8	6	+33.3%
Increased positions	30	37	-18.9%
Reduced positions	13	10	+30.0%

13F shares	Current	Prev Q	Change
Total value	193.71 bn	268.38 bn	-27.8%
Total shares	38.55 mm	38.20 mm	+0.9%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
JHG Janus Henderson	4.34 mm	$28.51 bn	+15.3%
Longitude Capital Partners IV	2.77 mm	$22.90 mm	0.0%
Citadel Advisors	2.72 mm	$17.92 bn	0.0%
Adage Capital Partners GP, L.L.C.	2.21 mm	$14.54 bn	-14.9%
Adage Capital Management	2.21 mm	$11.60 mm	-14.9%
D1 Capital Partners	2.20 mm	$14.50 bn	-12.1%
MFG Mizuho Financial	1.93 mm	$10.12 mm	NEW
BlackRock	1.82 mm	$11.99 bn	+11.8%
Eventide Asset Managment	1.23 mm	$8.13 bn	-33.5%
Vestal Point Capital	1.20 mm	$7.90 bn	+41.2%

Largest transactions	Shares	Bought/sold	Change
MFG Mizuho Financial	1.93 mm	+1.93 mm	NEW
Omega Fund Management	1.18 mm	-1.17 mm	-49.7%
Omega Fund VI	1.18 mm	-972.99 k	-45.1%
Braidwell	0.00	-728.78 k	EXIT
Eventide Asset Managment	1.23 mm	-621.15 k	-33.5%
JHG Janus Henderson	4.34 mm	+576.06 k	+15.3%
Altium Capital Management	405.00 k	+405.00 k	NEW
Adage Capital Partners GP, L.L.C.	2.21 mm	-388.12 k	-14.9%
Adage Capital Management	2.21 mm	-388.12 k	-14.9%
Point72 Asset Management	750.24 k	+379.83 k	+102.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

LXEO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
19 Feb 25	Jenny Robertson	Common Stock	Sell	Dispose S	No	No	4.413	2,101	9.27 k	57,899
19 Feb 25	Tai Sandi See	Common Stock	Sell	Dispose S	No	No	4.413	1,486	6.56 k	53,889
19 Feb 25	Richard Nolan Townsend	Common Stock	Sell	Dispose S	No	No	4.413	4,326	19.09 k	220,119
19 Feb 25	Eric Adler	Common Stock	Sell	Dispose S	No	No	4.413	2,359	10.41 k	68,266
17 Jan 25	Kyle Rasbach	Common Stock	Grant	Acquire A	No	No	0	40,875	0.00	40,875
17 Jan 25	Kyle Rasbach	Stock Option Common Stock	Grant	Acquire A	No	No	5.07	245,250	1.24 mm	245,250

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

5 Feb 25

RBC Capital Reiterates Outperform on Lexeo Therapeutics, Maintains $24 Price Target

21 Jan 25

RBC Capital analyst Luca Issi reiterates Lexeo Therapeutics (NASDAQ:LXEO) with a Outperform and maintains $24 price target.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

31 Dec 24

Press releases

From Benzinga Pro

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

7 Jan 25

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases, today

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

19 Dec 24

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and